141 related articles for article (PubMed ID: 23563604)
1. Targeting the A3 adenosine receptor for glaucoma treatment (review).
Fishman P; Cohen S; Bar-Yehuda S
Mol Med Rep; 2013 Jun; 7(6):1723-5. PubMed ID: 23563604
[TBL] [Abstract][Full Text] [Related]
2. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.
Baharav E; Bar-Yehuda S; Madi L; Silberman D; Rath-Wolfson L; Halpren M; Ochaion A; Weinberger A; Fishman P
J Rheumatol; 2005 Mar; 32(3):469-76. PubMed ID: 15742438
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101.
Bar-Yehuda S; Luger D; Ochaion A; Cohen S; Patokaa R; Zozulya G; Silver PB; de Morales JM; Caspi RR; Fishman P
Int J Mol Med; 2011 Nov; 28(5):727-31. PubMed ID: 21887476
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression.
Ochaion A; Bar-Yehuda S; Cohn S; Del Valle L; Perez-Liz G; Madi L; Barer F; Farbstein M; Fishman-Furman S; Reitblat T; Reitblat A; Amital H; Levi Y; Molad Y; Mader R; Tishler M; Langevitz P; Zabutti A; Fishman P
Arthritis Res Ther; 2006; 8(6):R169. PubMed ID: 17101059
[TBL] [Abstract][Full Text] [Related]
5. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Avni I; Garzozi HJ; Barequet IS; Segev F; Varssano D; Sartani G; Chetrit N; Bakshi E; Zadok D; Tomkins O; Litvin G; Jacobson KA; Fishman S; Harpaz Z; Farbstein M; Yehuda SB; Silverman MH; Kerns WD; Bristol DR; Cohn I; Fishman P
Ophthalmology; 2010 Jul; 117(7):1287-93. PubMed ID: 20304499
[TBL] [Abstract][Full Text] [Related]
6. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment.
Bar-Yehuda S; Rath-Wolfson L; Del Valle L; Ochaion A; Cohen S; Patoka R; Zozulya G; Barer F; Atar E; Piña-Oviedo S; Perez-Liz G; Castel D; Fishman P
Arthritis Rheum; 2009 Oct; 60(10):3061-71. PubMed ID: 19790055
[TBL] [Abstract][Full Text] [Related]
7. Activation of Adenosine A
Ferreira-Silva J; Aires ID; Boia R; Ambrósio AF; Santiago AR
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007835
[TBL] [Abstract][Full Text] [Related]
8. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
Silverman MH; Strand V; Markovits D; Nahir M; Reitblat T; Molad Y; Rosner I; Rozenbaum M; Mader R; Adawi M; Caspi D; Tishler M; Langevitz P; Rubinow A; Friedman J; Green L; Tanay A; Ochaion A; Cohen S; Kerns WD; Cohn I; Fishman-Furman S; Farbstein M; Yehuda SB; Fishman P
J Rheumatol; 2008 Jan; 35(1):41-8. PubMed ID: 18050382
[TBL] [Abstract][Full Text] [Related]
9. Activation of adenosine A
Boia R; Salinas-Navarro M; Gallego-Ortega A; Galindo-Romero C; Aires ID; Agudo-Barriuso M; Ambrósio AF; Vidal-Sanz M; Santiago AR
Cell Death Dis; 2020 May; 11(5):401. PubMed ID: 32461578
[TBL] [Abstract][Full Text] [Related]
10. CF101 for dry eye.
Ashar JN; Mathur A; Sangwan V
Ophthalmology; 2011 May; 118(5):1011-2; author reply 1012. PubMed ID: 21539995
[No Abstract] [Full Text] [Related]
11. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.
Cohen S; Stemmer SM; Zozulya G; Ochaion A; Patoka R; Barer F; Bar-Yehuda S; Rath-Wolfson L; Jacobson KA; Fishman P
J Cell Physiol; 2011 Sep; 226(9):2438-47. PubMed ID: 21660967
[TBL] [Abstract][Full Text] [Related]
12. Knockout of A3 adenosine receptors reduces mouse intraocular pressure.
Avila MY; Stone RA; Civan MM
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3021-6. PubMed ID: 12202525
[TBL] [Abstract][Full Text] [Related]
13. CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.
Bar-Yehuda S; Madi L; Silberman D; Gery S; Shkapenuk M; Fishman P
Neoplasia; 2005 Jan; 7(1):85-90. PubMed ID: 15720820
[TBL] [Abstract][Full Text] [Related]
14. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis.
Fishman P; Bar-Yehuda S; Madi L; Rath-Wolfson L; Ochaion A; Cohen S; Baharav E
Arthritis Res Ther; 2006; 8(1):R33. PubMed ID: 16507132
[TBL] [Abstract][Full Text] [Related]
15. Adenosine, adenosine receptors and glaucoma: an updated overview.
Zhong Y; Yang Z; Huang WC; Luo X
Biochim Biophys Acta; 2013 Apr; 1830(4):2882-90. PubMed ID: 23328492
[TBL] [Abstract][Full Text] [Related]
16. Ocular Purine Receptors as Drug Targets in the Eye.
Jacobson KA; Civan MM
J Ocul Pharmacol Ther; 2016 Oct; 32(8):534-547. PubMed ID: 27574786
[TBL] [Abstract][Full Text] [Related]
17. Identification of the A3 adenosine receptor in rat retinal ganglion cells.
Zhang M; Budak MT; Lu W; Khurana TS; Zhang X; Laties AM; Mitchell CH
Mol Vis; 2006 Aug; 12():937-48. PubMed ID: 16943766
[TBL] [Abstract][Full Text] [Related]
18. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.
Fishman P; Cohen S
Clin Rheumatol; 2016 Sep; 35(9):2359-62. PubMed ID: 26886128
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-n-methyluronamide in human leukemia cells.
Mlejnek P; Dolezel P; Kosztyu P
J Cell Physiol; 2012 Feb; 227(2):676-85. PubMed ID: 21520073
[TBL] [Abstract][Full Text] [Related]
20. Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma.
Schlötzer-Schrehardt U; Zenkel M; Decking U; Haubs D; Kruse FE; Jünemann A; Coca-Prados M; Naumann GO
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2023-34. PubMed ID: 15914619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
